• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Arrowhead Pharmaceuticals (ARWR), What Is Behind Its Latest Update?

    Simply Wall St·10/27/2026 10:26:52
    Listen to the news

    Why ARO-MAPT Matters For Arrowhead Pharmaceuticals Stock

    Arrowhead Pharmaceuticals (ARWR) just released interim Phase 1/2a data for ARO-MAPT, showing substantial cerebrospinal fluid tau reductions in healthy volunteers after subcutaneous dosing, with treatment generally well tolerated.

    ARO-MAPT's interim readout lands after a choppy year for Arrowhead Pharmaceuticals, with the share price up 49.39% on a 1-year total shareholder return. However, the 90-day share price return is down 31.24%, hinting that enthusiasm is being recalibrated as trial risk and valuation expectations reset around the US$58.98 level.

    Spot 34 healthcare AI stocks that, like Arrowhead Pharmaceuticals today, are trying to turn complex biology and data into meaningful potential breakthroughs for patients.

    Bulls point to Arrowhead Pharmaceuticals' RNAi platform validation and ARO-MAPT data, while bears focus on trial risk, losses and a sharp recent pullback. Which side does the current US$58.98 valuation lean toward?

    Most Popular Narrative: 46% Undervalued

    Arrowhead Pharmaceuticals last closed at $58.98, while the most followed narrative framework puts fair value at about $110.18, implying a wide valuation gap that hinges on how investors view the RNAi pipeline and partnership economics.

    Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, is seen as positioning the company to potentially benefit from demand for treatments for chronic and genetic diseases as approvals and launches materialize.

    Multiple large pharma collaborations and milestone-generating partnerships, notably with Sarepta, Amgen, Takeda, and Sanofi, provide non-dilutive capital, revenue diversity, and stability that is less dependent on equity markets, supporting ongoing R&D investments and adding visibility to medium-term cash flow.

    See why 14 investors see Arrowhead Pharmaceuticals as 46% undervalued.

    Result: Fair Value of $110.18 (UNDERVALUED)

    Still, Arrowhead Pharmaceuticals relies heavily on unpredictable milestone payments and faces rising trial and commercial buildout costs, which could strain cash if timelines slip.

    Find out about the key risks to this Arrowhead Pharmaceuticals narrative.

    Next Steps

    If this mix of optimism and concern around Arrowhead Pharmaceuticals feels familiar, use it as a prompt to review the data yourself and move quickly to your own conclusion, then weigh up the balance of 3 key rewards and 2 important warning signs.

    Looking For More Arrowhead Pharmaceuticals Style Ideas?

    If Arrowhead Pharmaceuticals has your attention, do not stop here. Use the Simply Wall Street Screener to surface fresh ideas before the crowd does.